StockNews.AI
PTGX
StockNews.AI
13 days

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

1. Protagonist filed NDA for icotrokinra for psoriasis; pivotal trial data upcoming. 2. Company reported significant financial health with $673 million cash reserves.

3m saved
Insight
Article

FAQ

Why Bullish?

The NDA filing for icotrokinra could boost PTGX's value, similar to past FDA approvals that led to substantial price surges in biotech stocks.

How important is it?

The NDA filing represents a critical milestone for PTGX, likely to attract investor interest and enhance market confidence.

Why Short Term?

The upcoming data presentation and NDA approval process may influence PTGX's price swiftly due to investor sentiment.

Related Companies

VRTXAMGNBIIB
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th Phase 3 VERIFY trial data set of rusfertide in polycythemia vera (PV) presented during plenary session at ASCO; U.S. NDA filing on track for Q4 Cash, cash equivalents and marketable securities of $673.0 million as of June 30, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / August 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. "Thus far, 2025 has been a year of breakthrough accomplishments for Protagonist, as we saw rusfertide the topic of the prestigious ASCO Plenary Session in May, the announcement of an oral and injectable triple agonist anti-obesity peptide development candidate in June, and most recently the first ever NDA filing of icotrokinra for psoriasis last month," said Dinesh V.

Related News